Latest News and Press Releases

The study showed that orelabrutinib was safe and well tolerated in participants with SLE.

InnoCare's novel BCL2i mesutoclax in MDS and AML was released at 2026 ASCO as an oral presentation, demonstrating outstanding efficacy and safety.

This is the first NDA acceptance for BTK inhibitor orelabrutinib in autoimmune diseases. No BTK inhibitors have been approved in China for ITP.

Orelabrutinib (HIBRUKA®) has been approved by TGA in Australia, offering a new treatment option for patients with R/R MCL in the region.

The data show that mesutoclax demonstrates outstanding efficacy and safety in treating various hematologic malignancies.

- Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ICP-054 (ZB021) in healthy volunteers - Phase 1 SAD and MAD data expected by year-end 2026 BEIJING,...

ICP-488 is expected to provide a novel therapeutic option for patients. There are no approved targeted therapies for Sjögren's syndrome globally.

The IND approval marks another milestone in our solid tumor pipeline and validates the huge drug development potential of our ADC platform.

Orelabrutinib is the first BTKi to demonstrate significant efficacy in a Phase II clinical trial for SLE, which affects around 8 million people worldwide.

InnoCare remained profitable in the first quarter of 2026, with net profit increasing by 607.7% YoY to RMB 102.4 million.